Cargando…

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa

BACKGROUND: Efanesoctocog alfa is a new class of factor (F) VIII replacement therapy designed to provide high sustained factor levels for longer by overcoming the von Willebrand factor half-life ceiling. OBJECTIVES: To assess the pharmacokinetics and safety of standard half-life (octocog alfa) and e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lissitchkov, Toshko, Willemze, Annemieke, Jan, Christelle, Zilberstein, Moshe, Katragadda, Suresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394562/ https://www.ncbi.nlm.nih.gov/pubmed/37538505 http://dx.doi.org/10.1016/j.rpth.2023.100176

Ejemplares similares

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
por: Lissitchkov, Toshko, et al.
Publicado: (2022)

Efanesoctocog Alfa: First Approval
por: Keam, Susan J.
Publicado: (2023)

Correction to: Efanesoctocog Alfa: First Approval
por: Keam, Susan J.
Publicado: (2023)

A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States
por: Aledort, Louis, et al.
Publicado: (2020)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Octocog alfa: Lack of efficacy: case report
Publicado: (2022)

Convenience Comparison Study of Reconstitution Devices for the Blood Coagulation Factor VIII Products Rurioctocog Alfa Pegol and Antihemophilic Factor (Recombinant)
por: Ueda, Hitoshi, et al.
Publicado: (2020)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients
por: You, Chur Woo, et al.
Publicado: (2019)

Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials
por: Witarto, Bendix Samarta, et al.
Publicado: (2022)

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety
por: Stidl, Reinhard, et al.
Publicado: (2018)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021)

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study
por: Escuriola-Ettingshausen, Carmen, et al.
Publicado: (2023)

Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Efficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and Alloantibodies
por: Sottilotta, Gianluca, et al.
Publicado: (2017)

External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data
por: Chelle, Pierre, et al.
Publicado: (2021)

Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial
por: Gruppo, Ralph, et al.
Publicado: (2019)

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A
por: Korth‐Bradley, Joan, et al.
Publicado: (2018)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

ALFA
por: Hiller, Karlheinz
Publicado: (2012)

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program
por: Lissitchkov, Toshko, et al.
Publicado: (2019)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth, Robert, et al.
Publicado: (2021)

ALFA - Absolute Luminosity measurement For Atlas alias ALFA in ATLAS
por: Sykora, Tomas
Publicado: (2008)

Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development
por: Abramova, Nadezda, et al.
Publicado: (2018)

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
por: George, Lindsey A, et al.
Publicado: (2015)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
por: Napolitano, Mariasanta, et al.
Publicado: (2019)

Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization
por: Huffaker, Michelle F., et al.
Publicado: (2019)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

The ALFA Trigger Simulator
por: Dziedzic B, et al.
Publicado: (2015)

ALFA beam halo
por: Komarek, Tomas
Publicado: (2014)

Methods in ALFA Alignment
por: MELENDEZ, Jordan
Publicado: (2014)

Methods in ALFA Alignment
por: Melendez, Jordan
Publicado: (2014)

Alfa e Omega
Publicado: (2009)

ATLAS-ALFA Meeting
Publicado: (2010)

Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real‐world study, TAURUS
por: Santoro, Cristina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j5hoasjlh3dr5brt4von760vfp